У нас вы можете посмотреть бесплатно Q & A with Sharon's son, George Episode 253. Special Guest: Jennifer Johnston CEO at NysnoBio или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Q & A with Sharon's son, George Episode 253. Special Guest: Jennifer Johnston CEO at NysnoBio, YOPD and therapeutic intervention for Parkin and LRRK2 enzymes, genetic causes of Parkinson’s. TogetherForSharon® In memory of my mother, Sharon to voice awareness & hope for a Parkinson's Disease cure. Listen to The TogetherForSharon® Podcast on Spotify https://open.spotify.com/episode/3TpX... Dr. Johnston has been studying neurodegenerative disease for the last 24 years, beginning at Stanford, with the discovery and description of Aggresomes. This discovery provided the first example of cellular proteostasis and defined a new cellular pathway to understand the canonical accumulation of ubiquitin in neurodegenerative disease. Prior to Stanford, work at Caltech defined protein unfolding requirements for protein degradation by the proteasome, and small molecules that can regulate protein degradation by stabilizing protein structure. At Elan Pharmaceuticals, as VP and Head of Exploratory Research, she directed over 30 drug discovery programs for small molecule and antibody therapeutics for Parkinson’s and Alzheimer’s disease. Dr. Johnston personally led a small molecule drug discovery program on Parkin E3 Ubiquitin ligase, discovering and publishing the first small molecules to activate the enzyme. Her team also provided the first high resolution crystal structure of the enzyme, described the autoinhibited state, and the novel active site of the enzyme. Presently, she is the Co-Founder and CEO of FinsoBio, a company focused on small molecules that regulate Parkin and LRRK2 enzymes genetically linked to Parkinson’s Disease, and the Co-Founder and CEO of NysnoBio, a company focused on gene therapy approaches to restore Parkin protein function in Parkinson’s Disease. She is also CEO and founder of NysnoBioMetrix, a non-profit founded to provide outreach and informational services for young onset Parkinson’s patients. https://www.michaeljfox.org/news/hono... nysnobio.com @nysnobio3784 @TheParkinsonsConnectionYouTube @michaeljfoxfoundation @NIHgov